Bristol-Myers Squibb

Bristol Myers Squibb commits $300 million to combat racial disparities and double number of Black, Latino executives
Endpoints
Wed, 08/12/20 - 10:48 am
Bristol-Myers Squibb
clinical trials
racial diversity
racial disparity
Bristol Myers Squibb’s Opdivo Hits Mark in Two Phase III Studies
BioSpace
Wed, 08/12/20 - 12:31 am
Bristol-Myers Squibb
Opdivo
clinical trials
gastric cancer
esophageal cancer
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
Sat, 08/8/20 - 10:46 pm
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug
BioPharma Dive
Thu, 08/6/20 - 10:27 am
Bristol-Myers Squibb
Pfizer
patents
Eliquis
generics
Delaware
Roche’s Tecentriq claims melanoma OK, but don’t expect a sales surge
Pharmaforum
Fri, 07/31/20 - 10:43 am
Roche
Tecentriq
FDA
melanoma
Bristol-Myers Squibb
Merck
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Thu, 07/30/20 - 12:01 am
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
Mon, 07/20/20 - 11:49 pm
R&D
drug development
Eli Lilly
Novartis
Argenx
Bristol-Myers Squibb
Vir Biotechnolgy
Biogen
GSK
Iovance
Roche
BMS launches digital Advocacy Exchange for patient groups affected by COVID-19
Pharmaforum
Wed, 06/24/20 - 10:09 am
Bristol-Myers Squibb
GRYT Health
COVID-19
pandemic
patients
digital health
Third-quarter events to watch for large drug makers
EP Vantage
Mon, 06/22/20 - 10:35 am
Biogen
aducanumab
Sanofi
THOR-707
Bristol-Myers Squibb
pegbelfermin
Eli Lilly
FDA
After Celgene deal, BMS shoots up pharma market cap rankings
Pharmaforum
Sun, 06/21/20 - 10:51 pm
Bristol-Myers Squibb
Celgene
M&A
Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda
Endpoints
Wed, 06/17/20 - 10:48 am
Merck
Keytruda
Bristol-Myers Squibb
FDA
biomarkers
accelerated approvals
cancer
TMB
Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer
Pharmaceutical Business Review
Thu, 06/11/20 - 11:16 am
Clovis Oncology
clinical trials
Rubraca
ovarian cancer
Opdivo
Bristol-Myers Squibb
Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer
Pharmaceutical Business Review
Wed, 06/10/20 - 10:54 am
UbiVac
Bristol-Myers Squibb
clinical trials
triple negative breast cancer
DPV-001
Bristol's Celgene merger sees it bounce Jounce drug pact
Fierce Biotech
Fri, 06/5/20 - 10:43 am
Bristol-Myers Squibb
Celgene
Jounce Therapeutics
M&A
immuno-oncology
ASCO 2020 round-up: Virtual conference still delivers the drama ASCO 2020 round-up: Virtual conference still delivers the drama
Pharmaforum
Fri, 06/5/20 - 10:30 am
ASCO 2020
Amgen
AstraZeneca
Bristol-Myers Squibb
cancer
CAR-T
COVID-19
Keytruda
Kyprolis
Tagrisso
FDA approval tracker: several early decisions in May
EP Vantage
Wed, 06/3/20 - 10:24 am
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
BMS' Recently Approved MS Drug Shows Promise in Ulcerative Colitis Study
BioSpace
Tue, 06/2/20 - 11:20 pm
Bristol-Myers Squibb
Zeposia
ozanimod
ulcerative colitis
Bristol Myers Squibb's Zeposia launches into crowded MS market
Fierce Pharma
Tue, 06/2/20 - 10:50 am
Bristol-Myers Squibb
Celgene
Zeposia
drug launches
MS
multiple sclerosis
IPOs abound in the time of coronavirus, as Forma Therapeutics pencils in $150M Nasdaq debut
Endpoints
Mon, 06/1/20 - 10:48 am
IPOs
NASDAQ
Forma Therapeutics
Bristol-Myers Squibb
COVID-19
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO
Xconomy
Sat, 05/30/20 - 08:02 pm
cancer
IPOs
Repare Therapeutics
Bristol-Myers Squibb

Pages